Economic Evaluation Ken Stein Public Health Physician North & East Devon Health Authority University of Exeter.

Slides:



Advertisements
Similar presentations
Workshop C – Evaluation Rod Taylor Complex Interventions Research Framework Masterclass 2010.
Advertisements

1 Alternative measures of well-being Joint work by ECO/ELSA/STD.
Comparing different treatments How can we decide?.
Elicitation methods Health care demands exceed resource supply Therefore, rationing is inevitable Many ways by which we can ration health care One is economic.
Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.
ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
USE OF EVIDENCE IN DECISION MODELS: An appraisal of health technology assessments in the UK Nicola Cooper Centre for Biostatistics & Genetic Epidemiology,
USE OF EVIDENCE IN DECISION MODELS: An appraisal of health technology assessments in the UK Nicola Cooper Centre for Biostatistics & Genetic Epidemiology,
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Step 5: Communication and Evaluation. Table of Contents Communication Communicate with Your Patients Video 1 Communicate with Health Professionals Evaluation.
Paul Tappenden Jim Chilcott Health Economics and Decision Science (HEDS) School of Health and Related Research (ScHARR) 25 th July 2005 Consensus working.
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
Session 2: Assessing cost- effectiveness of individual level interventions ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research.
Implementation of new technologies Dr Keith Cooper Southampton Health Technology Assessments Centre University of Southampton.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Introduction to Pharmacoeconomics
Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.
“Rational Pharmacology” and Health Economics By Alan Maynard.
Overview of the day Introduction to Health Economics Introduction to Economic Evaluations LUNCH Appraising Economic.
Decision Analysis Prof. Carl Thompson
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Clare A Mackie Centre for Partnerships in Medicines for Health Economic Evaluation of a RCT of a ‘Medication Review Clinic’ in Patients Receiving Repeat.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
These slides were released by the speaker for internal use by Novartis.
PHAR 310: Pharmacoeconomics
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.
Systematic Reviews.
Cost-Effectiveness Thresholds Professor of Health Economics
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
Vanderbilt Sports Medicine Chapter 5: Therapy, Part 2 Thomas F. Byars Evidence-Based Medicine How to Practice and Teach EBM.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
DIFFICULT DECISIONS IN HEALTH CARE Presentation to OJHOSC Dr Ljuba Stirzaker Oxfordshire Primary Care Trust 13 March 2008 ITEM JHO8(a) JHO3.MAR1308R03.ppt.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
EBM --- Journal Reading Presenter :葉麗雯 Date : 2005/10/27.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Benjamin Kearns, The University of Sheffield
Cost effectiveness Analysis: Valuing Health; Valuing Research!
Global burden of diseases
For a copy of the poster:
Economic Evaluation of Health Interventions Basic Concepts
Mechanical thrombectomy
Health care decision making
Sergio Bautista-Arredondo National Institute of Public Health Mexico
Assessing value for money: principles, methods and issues
Health Economics for Prescribers
Measuring outcomes Emma Frew October 2012.
Economic Evaluation in Health Care
Presentation Developed for the Academy of Managed Care Pharmacy
Diabetic Retinopathy Clinical Research Network
Presentation transcript:

Economic Evaluation Ken Stein Public Health Physician North & East Devon Health Authority University of Exeter

Questions Can it work? Efficacy Does it work? Effectiveness Should it be used, given other calls on a fixed budget? Economics Is it reaching those whom it should? Availability EBM Policy Audit Development

A national problem Higgenbottoms syndrome is now recognised as a national problem There are grave concerns about a lottery of postcode dancing NICE takes action... Your PCT is not convinced and asks you to review the evidence You need some background to deal with the results of your search and the NICE evaluation

Economic analysis involves Identification of alternatives … their consequences … and their costs … the values of these … and how they compare … to inform the decision on whether you should do it

Spotting economic analyses Is there a comparison of two or more alternatives? Are both costs and consequences examined? If not - the study is not an economic evaluation but may be: description of costs or outcomes evaluation of efficacy or effectivenes cost analysis

CHOICE Treatment A Treatment B Consequences PERSPECTIVE...

Types of economic analysis Cost minimisation Cost effectiveness Cost utility Cost benefit

Defining economic analyses

Cost effectiveness How much it costs to get an effect e.g. how much per fight prevented by ballet therapy? i.e the RATIO of COSTS to EFFECTS How might different cost effectiveness ratios for alternative treatments appear? The cost effectiveness plane

Alternative less effective and more costly E Alternative cheaper but less effective D Alternative more effective and less costly C E.g. £20,000 per QALY COST OUTCOME A B Alternative more effective but more costly

Marginal (syn: incremental) or average analysis? An analysis of different doses of a cholesterol lowering drug shows that 80mg per day gives a cost effectiveness of £25,000 per life year gained (LYG) 40mg per day gives £15,000 per LYG So its probably worth giving 80mg where possible as the extra LYG costs only £10,000? Well...

COST LYG £25,000/LYG £15,000/LYG £85,000/LYG 80mg 40mg

Marginal cost effectiveness = whats the extra cost to get the extra effectiveness? i.e. Difference in costs Difference in effectiveness

Quality Adjusted Life Years A 1985, good quality, 10 year cohort study of HS showed: Life expectancy is reduced by one year compared to national life tables HS sufferers spent, on average: 120 person days per year with: –limited mobility –episodic incontinence –moderate pain –depression of mood

QALY burden of HS 100 people with HS will, over 10 years: lose 100 life years lose 100 x 0.3 years of full quality of life

Utilities and QALYs Utility is a measure of preference about an outcome (a health state), giving an indication of the relative value placed on the health state Scaled 0 (death) to 1 (full health) Utilities are used to weight time according to quality of life spent during that time A health state with a utility of 0.5 lasting two years is equivalent to one year in full health Allows us to consider differences in treatments which involve changes in quality as well as quantity of life

QALY gains - example QALYs - patient 1 QALYs - patient 2 QALYs gained Death LYG gained

Utitilies and HS Description of HS health states to experts for opinion (Dr Phillips says utlity = 0.95 ) Eliciting utilities with HS sufferers –Visual analogue scale –Time trade off (utility = 0.67) –Standard Gamble Mapping onto health state measures for which preferences are known e.g. EQ5D –Mobility –Self-care –Usual activity (utility = 0.85) –Pain / discomfort –Anxiety / depression PS - these are the real values for utilities associated with impotence used in an evaluation of the cost utility of viagra

The NICE appraisal Was a well defined question posed? TITLE: Cost effectiveness and Cost Utility of Ballet Therapy for Higginbottoms Syndrome - a report to NICE, January 2001 Perspective was the NHS, with potential impacts on non-health sector identified but not included in the analysis

Was a comprehensive description of competing alternatives given? Intervention: Fonteyns model for ballet therapy Comparator: do nothing

Was the analysis based on valid evidence? Fonteyn M et al five year RCT of Ballet therapy for HS Number of fights prevented = 13 per year

Were all important and relevant resources identified for each alternative? Costs Ballet therapy - GP, specialist community dancing support team, capital for ballet schools, trainer costs, follow up, replacement dresses. Identified from micro-costing study Savings Healthcare costs associated with HS, estimated from National reference costs for HRGs Outcomes Number of fights QALYs based on healthstates associated with fights and treatment, valued by expert opinion

Results Ballet therapy costs an average of £14,756 per year Savings to the NHS: £4,875 per year Total costs to the NHS of implementing ballet therapy would be £483m over 5 years Incremental benefits would be: 13 fights prevented 0.24 QALYs gained

Results COST OUTCOME Cost per fight averted = £744

Results COST OUTCOME Cost per QALY = £41,230 £20,000 per QALY

Were healthcare use and health outcome consequences adjusted for the different times at which they occurred? Undiscounted Year 1 costs = 1,000 Year 2 costs = 1,000 Year 3 costs = 1,000 Year 4 costs = 1,000 Year 5 costs = 1,000 6% Year 1 = £1000 Year 2 = £943 Year 3 = £890 Year 4 = £840 Year 5 = £792 TOTAL = £4,465

Was an adequate sensitivity analysis performed? One way sensitivity analysis on costs and outcomes (number of fights, utilities associated with health states) showed results reasonably stable Cost effectiveness: £530 to £2400 / FP Cost utility: £35,000 to £56,000 per QALY (over 5 years - no modelling beyond the end of the trial undertaken) Dress and ballet trainer costs were most influential in the sensitivity analysis

Will the results help you? Were the conclusions justified? Can the results be applied to your population? Effectiveness of ballet therapy? Implementation costs different (shortage or excess of ballet trainers, availability of dresses, dispersed population)? Costs of healthcare (savings) different? Organisation of the healthcare system? Discounting rate may differ?

Appraisal decision Ballet therapy is an effective treatment but benefits are modest compared to other calls on the NHS budget. Considerable uncertainty remains over the long term effects of ballet therapy and further research is required, incorporating an economic analysis from a broader societal perspective… The International Confederation of Ballet Trainers has contested this decision